Replies to post #114696 on Biotech Values

[DewDiligence]

I’m not keeping such a compilation, but I’ve noticed that most sell-side analysts accept what Teva says at face value in spite of the obvious disconnect between Teva’s prior pronouncements and reality. In Pavlovian style, some analysts fill in the blanks with stuff Teva never even stated but merely encouraged analysts to think—e.g. that Teva has only minor issues outstanding on the Lovenox ANDA.